We take a full-circle approach to product development, from the grassroots level to the lab to legislative bodies.


To translate scientific discoveries into affordable, globally accessible public health solutions.


A world where all people have equitable access to innovative vaccines and therapeutics.

Our health areas

  • HIV
  • Tuberculosis
  • Lassa fever
  • Marburg virus
  • Sudan Ebolavirus
  • COVID-19


The challenge

HIV/AIDS remains one of the deadliest infectious diseases, with 1.3 million people acquiring HIV in 2022. Given the complexities of HIV, traditional approaches to vaccine development have so far failed to result in a vaccine that provides protection against HIV. However, a vaccine is still needed to bring a true end to the HIV pandemic. Source: UNAIDS

Our solution

IAVI scientists and our collaborators are developing next-generation HIV vaccines to address the challenges of HIV vaccine design. Together, we have pioneered promising new vaccination strategies and the discovery of broadly neutralizing antibodies (bnAbs) against HIV. IAVI and our partners are developing HIV bnAbs to prevent HIV acquisition while we advance vaccine candidates.


The challenge

Tuberculosis (TB) is the world’s leading infectious disease killer. In 2022, 10.6 million people fell ill with TB and 1.3 million people died of TB disease. The only available TB vaccine is the century-old Bacille Calmette-Guérin, or BCG. While this vaccine has efficacy in protecting against severe TB disease in infants and young children, it is largely ineffective in adolescents and adults, among whom most transmission and disease occurs. Source: WHO

Our solution

IAVI works across our global hubs with a diverse network of partners to advance the most promising TB vaccine candidates from discovery through clinical trials, and eventually, to post-licensure access. Our work extends to policy and advocacy initiatives that support TB vaccine development and access in regions where new vaccines are needed most.

Lassa fever

The challenge

Lassa fever is an acute viral hemorrhagic illness endemic to West Africa that causes significant annual outbreaks of disease. Lassa fever is difficult to diagnose, and surveillance data is limited. Current estimates range from 300,000 to 500,000 cases and 5,000 related deaths each year. No licensed vaccines for Lassa fever exist. Source: WHO

Our solution

IAVI is developing a single-dose vaccine candidate for Lassa that is based on a recombinant vesicular stomatitis virus (rVSV) vector. This technology is similar to that underlying an approved Ebola Zaire virus vaccine. IAVI’s Lassa vaccine candidate was well tolerated and immunogenic over a wide dose range in a Phase I clinical study. IAVI also conducts Lassa epidemiological studies and modeling to support future vaccine access.

Marburg virus

The challenge

Marburg virus is a filovirus and the causative agent of Marburg virus disease (MVD), which has a case fatality ratio of up to 88%. Marburg virus has the capacity to cause outbreaks with high fatality rates and is a potential bioterror threat. No vaccines or antiviral treatments are approved for MVD. A Marburg vaccine is urgently needed to respond to future outbreaks. Source: WHO

Our solution

IAVI is developing a vaccine candidate for Marburg that is based on a recombinant vesicular stomatitis virus (rVSV) vector. This technology is similar to that underlying an approved Ebola Zaire virus vaccine, which is now approved by the U.S. FDA and registered for use in several African countries. Preclinical data demonstrates that IAVI’s Marburg vaccine candidate is highly protective in an animal model with one dose.

Sudan Ebolavirus

The challenge

Sudan ebolavirus is a filovirus and causes outbreaks of Ebola disease, most recently in 2022 in Uganda. Case fatality rates of Ebola disease caused by Sudan ebolavirus have varied from 41% to 100% in past outbreaks. The licensed vaccine for Ebola Zaire virus does not provide cross protection against the Sudan strain. An Ebola Sudan vaccine is urgently needed to prevent and respond to future outbreaks. Source: WHO

Our solution

IAVI is developing a vaccine candidate for Sudan ebolavirus that is based on a recombinant vesicular stomatitis virus (rVSV) vector similar to the technology underlying an approved Ebola Zaire virus vaccine. During the 2022 Ebola outbreak in Uganda, the WHO selected IAVI’s Sudan ebolavirus vaccine candidate for a planned ring vaccination trial. While the trial did not go forward due to outbreak control, IAVI has continued clinical development to prepare for future outbreaks.


The challenge

Since December 2019, over 760 million cases of COVID-19 and 6.9 million deaths have been recorded worldwide, but the actual number is thought to be higher. While highly effective, approved COVID-19 vaccines do not fully block transmission or breakthrough infection. Additional COVID-19 vaccines continue to be an urgent need, particularly vaccines suitable for widespread use in middle and low-income countries. Source: WHO

Our solution

IAVI is developing a COVID-19 vaccine candidate that is based on a recombinant vesicular stomatitis virus (rVSV) vector. The vaccine candidate has demonstrated safety in humans when administered intramuscularly and has been produced at scale to support larger future clinical trials. IAVI is also investigating an intranasal formulation of our COVID-19 vaccine candidate to prevent infection.

Our impact

We conduct preclinical and clinical trials of our own vaccines and antibodies. Our focus is on diseases of global importance for which there is no market and little financial incentive for development. We also collaborate with and support other scientific organizations to conduct their own clinical trials of priority disease prevention and therapeutic interventions.

255 partners from academic, biotech, pharma sectors, civil society, and global health initiatives

53 biologics candidates supported by the IAVI Product Development Center, out of which 25 advanced to clinical trials

70,000 volunteers enrolled in observational epidemiology studies

Our locations

IAVI Africa

  • Cape Town Office, South Africa
  • Nairobi Office, Kenya

IAVI Europe

  • Amsterdam Office, The Netherlands
  • Human Immunology Lab, London, U.K.

IAVI India

  • Gurugram, Haryana Office
  • Antibody Translational Research Program, IAVI-THSTI, Faridabad


  • New York Office
  • Vaccine Design & Development Lab, New York
  • Neutralizing Antibody Center, California

Recent news & media

Kabelo Mabeleng prepares Duglas Netshidzivhani for a vaccine trial at the Aurum Institute Rustenberg, South Africa, in August 2022.

Championing domestic financing to promote a vibrant vaccine research and development enterprise in Africa

A central part of IAVI Africa’s role in translating research to global health impact is contributing to an enabling environment in which research and development (R&D) of global health solutions is conducted. In principle, the region’s governments acknowledge health as a productive sector contributing to socioeconomic growth and development. There is also consensus that domestic […]
Read More

Penta – Child Health Research announces new partnership with IAVI and Achilles Vaccines

Penta – Child Health Research announced today a new partnership with IAVI and Achilles Vaccines focused on the development of innovative monoclonal antibodies for pediatric HIV infections, for both preventive and therapeutic use. The partnership’s goal is to develop affordable, accessible new tools to address existing unmet needs for pediatric HIV. The partnership will additionally advance work targeting emerging infections and neglected diseases affecting children. Read Penta’s press release for more information.
Read More
Press Release

ReiThera Srl, the Ragon Institute and IAVI announce collaboration to advance highly networked T-cell HIV vaccine candidate towards Phase 1 clinical evaluation 

ROME, ITALY, NEW YORK and CAMBRIDGE, USA — January 22, 2024 — ReiThera Srl, the Ragon Institute of Mass General, MIT, and Harvard, and IAVI are pleased to announce a collaboration to develop a novel HIV vaccine candidate that will be composed of ReiThera’s GRAd vector and HIV T-cell epitopes identified by the Ragon Institute, funded by the Bill & Melinda Gates Foundation. Each partner will be responsible for a different aspect of the program: ReiThera will perform vector engineering and generation, process development, and good manufacturing practice(GMP) manufacture and release fo
Read More
Vials Clinical Trial

IAVI recommends new business models for increasing access to monoclonal antibodies

Together with partners Unitaid, the Medicines Patent Pool, and Wellcome, IAVI has released a set of new recommendations for improving access to monoclonal antibodies (mAbs) in low-income countries. Monoclonal antibodies are used today to treat cancers, autoimmune disorders, and are currently being explored as a new preventive and treatment tool for infectious diseases. Access to mAbs in low-income country contexts is extremely limited, and new approaches are needed to ensure access. Read more about the new business approaches that can advance mAb access.
Read More
POR Consortium

Development of the candidate tuberculosis vaccine H56:IC31 ended based on early data from the Prevention of Recurrence TB Consortium

The first analyses of data from the Phase IIb vaccine trial A-055 show that the tuberculosis (TB) vaccine candidate, H56:IC31, was well tolerated and demonstrated an immune response compared to the placebo in participants, all of whom had previously had TB. However, the primary analysis showed it did not provide protection against TB recurrence, reported Statens Serum Institut (SSI), IAVI, and trial partners who are part of the Prevention of Recurrence (POR) TB Consortium today. Based on these trial data, SSI has stopped development of the vaccine. A supporting analysis points in the directi
Read More